Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pfizer Inks Deal with Nanotechnology Drugmaker

By Pharmaceutical Processing | April 3, 2013

BIND Therapeutics said Wednesday that Pfizer Inc. has agreed to pay it $160 million per drug as part of a collaboration to develop targeted medicines using nanotechnology which use particles measured in billionths of a meter.

BIND is developing an experimental group of targeted, programmable medicines called Accurins to treat cancer, heart disease and inflammatory disorders. The privately held company’s technology comes from two laboratories that specialize in nanotechnology at Harvard Medical School and the Massachusetts Institute of Technology.

Pfizer will make initial payments of roughly $50 million, plus $160 million in regulatory and milestone payments for each targeted drug, according to an announcement from BIND.

Both companies will work on early-stage research for the drugs, and Pfizer will have the exclusive option to develop and market any products produced from the collaboration.

BIND has one product in early-stage clinical testing called Bind-014, a targeted Accurin that contains the chemotherapy drug docetaxel. The product is designed to attach itself to a protein that is expressed in some cancer cells and new blood vessels that feed tumors.

In an unrelated announcement Wednesday, the Children’s Hospital of Philadelphia said it will collaborate with Pfizer on therapies for children. Pfizer has research relationships with 21 academic hospitals throughout the U.S. with the aim of developing new products.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE